Vincent R. Anicetti - 06 Jul 2021 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role: Chief Operating Officer
Signature: /s/ McDavid Stilwell, as Attorney-in-Fact for Vincent R. Anicetti
Issuer symbol: CHRS
Transactions as of: 06 Jul 2021
Net transactions value: $0
Form type: 4
Filing time: 08 Jul 2021, 17:19:29 UTC
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CHRS	Common Stock	Award	$0	+50,000	+67%	$0.000000	124,790	06 Jul 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CHRS	Stock Option (Right to Buy)	Award	$0	+150,000		$0.000000	150,000	06 Jul 2021	Common Stock	150,000	$13.63	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/2 of the RSUs vest annually on July 6 of each year, with the first 1/2 vesting on July 6, 2022 and with the RSUs being fully vested on July 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
F2	Includes 122,083 RSUs and 1,388 shares of Common Stock purchased under Issuer's Employee Stock Purchase Plan on May 14, 2021 in a transaction exempt from Section 16(b) under Rule 16b3(c).
F3	The underlying shares subject to the option vest and become exercisable as to 1/24th of the total number of shares subject to the option in successive, equal monthly installments measured from July 6, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.